


**MELPHALAN**  
**CAS No. 148-82-3**

First Listed in the *First Annual Report on Carcinogens*



### CARCINOGENICITY

Melphalan is known to be a human carcinogen based on sufficient evidence of carcinogenicity in humans (IARC 1982, 1987). Epidemiological studies showed substantially increased rates of leukemia in patients treated with melphalan for the treatment of breast cancer, ovarian cancer, and multiple myeloma. The relative risk was consistently estimated to be in excess of 100, to increase with increasing dose, and to be comparable both with and without radiotherapy.

An IARC Working Group reported that there is sufficient evidence of carcinogenicity of melphalan in experimental animals (IARC 1975, 1982, 1987). When administered by intraperitoneal injection, melphalan induced lymphosarcomas in male mice, lung tumors in mice of both sexes, and peritoneal sarcomas in rats of both sexes.

### PROPERTIES

Melphalan is a white to buff-colored, odorless powder that is practically insoluble in water, but it is subject to rapid hydrolysis in water and plasma. It is soluble in ethanol, propylene glycol, alkaline solution, 2% carboxymethylcellulose, and dilute mineral acid. When heated to decomposition, it emits toxic fumes of hydrochloric acid and other chlorinated compounds as well as nitrogen oxides. Melphalan USP-grade powder, used to formulate tablets, contains 93.0% to 100.5% melphalan. The tablets are available in the U.S. as USP grade containing 2 mg active ingredient (HSDB 2001). It is sensitive to light and decomposes with storage (NTP 2001).

### USE

Melphalan is used in the palliative treatment of various malignant diseases, including breast and ovarian cancers, melanoma, and soft-tissue sarcomas, and to treat autoimmune disorders. It is also used as an insect chemosterilant, alkylating agent, and an antineoplastic in animals (IARC 1975, NTP 2001).

## PRODUCTION

One manufacturer in 1996 (HSDB 2001) and two suppliers in 2001 were reported in the U.S. (Chem Sources 2001). The USITC reported that in 1983 imports of melphalan totaled 363 lb (USTIC 1984), compared with an estimated 3,000 lb imported in 1977 (TSCA 1979). No data on exports were available.

## EXPOSURE

The primary routes of potential human exposure to melphalan are ingestion, injection, inhalation, and dermal contact. FDA estimates that 30,000 to 50,000 cancer patients may be treated with melphalan each year. Melphalan is administered orally or intravenously, at a dose rate of 2 to 15 mg daily for a period of 2 or 3 weeks (IARC 1975). Health professionals such as pharmacists, nurses, and physicians involved in cancer chemotherapy may possibly be exposed to melphalan. This exposure may occur during drug preparation, administration, or cleanup; however, the risks can be avoided through use of appropriate containment equipment and work practices (Zimmerman *et al.* 1981). A recent investigation has found that the exposure of hospital personnel to melphalan can be reduced by treating excess solutions, spills, and urinals with chlorine bleach (sodium hypochlorite, NaOCl, at 5.25%). No mutagenic residues are generated by the treatment, and complete degradation occurs in one hour (Hansel *et al.* 1997). Potential occupational exposure may also occur for workers involved in the formulation and packaging of the pharmaceuticals. The National Occupational Exposure Survey (1981-1983) estimated that 2,416 total workers, including 975 women, were potentially exposed to melphalan in the workplace (NIOSH 1984).

## REGULATIONS

EPA regulates melphalan under the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA) and the Resource Conservation and Recovery Act (RCRA). A reportable quantity (RQ) of 1 lb has been established for melphalan under CERCLA. It is listed as a hazardous constituent of waste and is regulated under the hazardous waste disposal rule of RCRA.

FDA has approved melphalan for treatment of myeloma and epithelial ovarian cancer under the Food, Drug, and Cosmetic Act (FD&CA). Melphalan is subject to labeling requirements for potential carcinogenicity, mutagenicity, teratogenicity, and/or fertility impairment under FD&CA.

OSHA regulates melphalan under the Hazard Communication Standard and as a chemical hazard in laboratories. Regulations are summarized in Volume II, Table 103.

## REFERENCES

Chem Sources. Chemical Sources International, Inc. <http://www.chemsources.com>, 2001.

Hansel, S., M. Castegnaro, M.H. Sportouch, M. De Méo, J.C. Milhavet, M. Laget, and G. Duménil. Chemical Degradation of Wastes of Antineoplastic Agents: Cyclophosphamide, Ifosfamide, and Melphalan. *Int. Arch. Occup. Environ. Health* Vol. 69, No. 2, 1997, pp. 109-114.

HSDB. Hazardous Substances Data Bank. Online database produced by the National Library of Medicine. Melphalan. Profile last updated August 9, 2001. Last review date, September 19, 1996.

IARC. International Agency for Research on Cancer. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Man. Some Aziridines, N-, S- and O-Mustards and Selenium. Vol. 9. 286 pp. Lyon, France: IARC, 1975.

IARC. International Agency for Research on Cancer. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans. Chemicals, Industrial Processes and Industries Associated with Cancer in Humans. Supplement 4. 292 pp. Lyon, France: IARC, 1982.

IARC. International Agency for Research on Cancer. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Overall Evaluations of Carcinogenicity. Supplement 7. 440 pp. Lyon, France: IARC, 1987.

NIOSH. National Institute for Occupational Safety and Health. National Occupational Exposure Survey (1980-83). Cincinnati, OH: Department of Health and Human Services, 1984.

NTP. National Toxicology Program. NTP Chemical Repository. Melphalan. Last updated August 9, 2001. (<http://ntp-server.niehs.nih.gov> and search 148-82-3).

TSCA. Toxic Substances Control Act, Chemical Substance Inventory, 1979: public record.

USITC. U.S. International Trade Commission. Imports of Benzenoid Chemicals and Products, 1983. USITC Publication No. 1548. Washington, DC: U.S. Government Printing Office, 1984.

Zimmerman, P.F., R.K. Larsen, E.W. Barkley, and J.F. Gallelli. Recommendations for the Safe Handling of Injectable Antineoplastic Drug Products. Am. J. Hosp. Pharm. Vol. 38, 1981, pp. 1693-1695.